Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China
ConclusionThe combination of anlotinib and PD-1 inhibitor has promising efficacy and manageable toxicity as a second- or later-line treatment of relapsed NSCLC and possibly for relapsed SCLC.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Chemotherapy | China Health | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Small Cell Lung Cancer | Study | Toxicology